International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

A Comparative Study of Biologic Regulation in US, Canada and Europe

[1]*Leelavathi A, [2]Bright Lemuel John N, [3]Pavithra D

[1]Department of Regulatory Affairs, JSS Academy of Higher Education & Research, Mysuru, India.
[2]Department of Pharmacology, PSG College of Pharmacy, Peelamedu, Coimbatore, India.

Received: 2025-05-10 Revised: 2025-05-28 Accepted: 2025-06-05

ABSTRACT

Developing a novel biological drug requires extensive research across multiple disciplines, including chemistry, manufacturing, controls, preclinical science, and clinical trials. Regulatory agencies around the world are responsible for evaluating whether the scientific evidence supports the safety, efficacy, and quality of new drug products to ensure public health protection. Each country has its own regulatory body tasked with enforcing drug laws, regulations, and approval guidelines. When seeking approval for a new drug, manufacturers must comply with the specific requirements of the relevant regulatory authority in each market. The global drug approval process is divided into various regional frameworks, which makes it essential for manufacturers to assess factors such as market potential, costs, target regions, and regulatory standards before launching a biologic. Although the ICH-CTD format is widely used, it still has certain limitations. This article explores the key factors involved in the approval of biological products in the United States, Canada and Europe.

Keywords: ICH Guidelines, Safety, CMC, Biologics



GRAPHICAL ABSTRACT

1. Introduction to Biologics

Biologics are a class of medical products that are derived from living organisms or contain components of living organisms. Unlike traditional small-molecule drugs, which are chemically synthesized, biologics are typically made through complex biotechnological processes involving cells or microorganisms. These products include a wide range of therapies such as monoclonal antibodies, vaccines, gene therapies, cell-based treatments, and recombinant proteins.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203

The development of biologics has revolutionized medicine, offering new treatment options for a variety of diseases, including cancer, autoimmune disorders, genetic conditions, and infectious diseases. Biologics often have the advantage of being more targeted and specific in their mechanisms of action compared to conventional drugs, which can result in better efficacy and fewer side effects for patients.

Due to their complexity, biologics present unique challenges in research, manufacturing, and regulation. Unlike traditional drugs, biologics cannot always be precisely replicated, and their production requires specialized facilities and highly controlled processes. As a result, biologic products are subject to rigorous regulatory oversight to ensure their safety, efficacy, and quality. Regulatory agencies around the world, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, set stringent guidelines for the approval, production, and marketing of biologics to protect public health.

The approval process for biologics is often more time-consuming and expensive than for conventional drugs, due to the extensive research and clinical trials required. Additionally, the global landscape for biologic approvals varies by region, with each country or jurisdiction having its own regulatory framework, standards, and requirements. However, international harmonization efforts, such as those led by the International Council for Harmonisation (ICH), aim to standardize certain aspects of the approval process, making it easier for manufacturers to navigate the regulatory pathways in different markets.

In this context, understanding the various regulatory frameworks and approval procedures for biologics across regions is crucial for manufacturers aiming to bring new biologic products to market. This chapter will explore the development, regulatory considerations, and approval processes for biologics in key regions, including the United States, Canada and Europe.

Figure.1 Role of Approval process

2. Manufacturing Process of Biologics

The manufacturing process of biologics is fundamentally different from that of traditional small-molecule drugs, due to the complex nature of biologic products. Biologics are derived from living organisms or biological systems, and their production requires advanced biotechnology techniques. These products are typically large, complex molecules such as proteins, antibodies, or cell therapies, and are produced using living cells as "factories" to synthesize the biologic substance. Here's an overview of the key steps involved in the manufacturing process of biologics:

2.1. Cell Line Development

The first step in the production of biologics is the development of a stable and efficient cell line that can produce the desired product. A cell line is a culture of cells that has been genetically modified to express the biologic product. This is typically done by inserting the gene encoding the protein or other biologic into a host cell, such as Chinese Hamster Ovary (CHO) cells **or** E. coli bacteria**,** which will then produce the desired substance.

- **Transfection**: The gene of interest is inserted into the host cell's DNA using methods such as viral vectors or electroporation.

- **Selection**: Only the cells that successfully integrate the gene are selected and cultured.

Once a stable cell line is developed, it will be expanded for production.

2.2. Upstream Processing

Upstream processing refers to the steps where the cells are grown and cultured to produce the biologic. This phase takes place in bioreactors or fermenters, where the cells are provided with the necessary nutrients, temperature, pH, and oxygen levels to maximize production.

- **Cell Culture**: Cells are cultured in a controlled environment, often in a bioreactor, where they grow and produce the target biologic protein.

- **Media and Feed Optimization**: The culture media (nutrient solutions) are optimized to support cell growth and protein expression. Feeding strategies are also used to boost production at certain stages.

- **Harvesting**: Once the cells have produced a sufficient quantity of the biologic, the culture is harvested. In the case of recombinant proteins or antibodies, this may involve collecting the product secreted into the culture medium or extracting it directly from the cells if it's intracellular.

2.3. Downstream Processing

Downstream processing involves the purification and concentration of the biologic product from the complex mixture of materials in the culture medium. This step is crucial to ensure that the final product is pure, safe, and free of contaminants.

- **Cell Lysis**: If the biologic is intracellular, the cells are lysed (broken open) to release the product.

- **Purification**: The product is purified using a series of techniques such as:

  - **Chromatography** (e.g., affinity, ion exchange, size exclusion): To separate the biologic from other proteins, DNA, and cell debris.

  - **Filtration**: To remove any residual cell debris, aggregates, or other impurities.

  - **Ultrafiltration**: To concentrate the biologic and exchange buffers if necessary.

- **Formulation**: The purified biologic is formulated into its final drug product form, which can include adding stabilizers, buffers, and excipients to preserve the stability and efficacy of the biologic.

2.4. Quality Control and Testing

Given the complexity of biologics, extensive quality control and testing are required at every step of production to ensure the safety, purity, and potency of the product.

- **Identity Testing**: Ensures that the biologic produced is the correct molecule and has the desired characteristics (e.g., glycosylation patterns, molecular weight).

- **Potency Assays**: Measures the biological activity of the product to confirm that it performs as intended.

- **Purity and Impurity Testing**: Ensures that contaminants (e.g., host cell proteins, endotoxins, residual DNA) are below acceptable limits.

- **Stability Studies**: Tests to ensure that the biologic maintains its quality over time, under various storage conditions.

2.5. Filling and Packaging

Once the biologic has passed quality control, it is prepared for distribution. The product is filled into its final dosage form, which may include vials, syringes, or pre-filled pens, depending on the biologic's intended use.

- **Aseptic Filling**: Because biologics are sensitive to contamination, the filling process is typically carried out in a highly controlled, sterile environment.

- **Packaging**: The filled biologic is packaged in appropriate materials that protect the product from degradation (e.g., light, temperature) and maintain sterility during storage and transport.

2.6. Regulatory Compliance and Documentation

Throughout the entire manufacturing process, manufacturers must comply with regulatory requirements set by agencies such as the FDA**,** EMA**,** and other global health authorities. This involves rigorous documentation at every step of the process to ensure traceability and compliance with Good Manufacturing Practices (GMP)**.** Inspections by regulatory bodies are routine to verify that manufacturers are meeting the necessary standards.

- **Batch Records**: Detailed records of each production batch, including cell line development, culture conditions, and purification processes, must be maintained.

- **Validation and Documentation**: Validation of the manufacturing process, equipment, and facilities is essential to ensure consistency, reproducibility, and product quality.

2.7. Distribution

Once the biologic is manufactured, it must be stored and transported under carefully controlled conditions (e.g., temperature-sensitive storage, cold chain logistics) to ensure that the product remains stable and effective until it reaches the patient.

Challenges in Biologic Manufacturing

- **Complexity and Variability**: The biological nature of the products means that even small changes in manufacturing conditions can result in significant differences in the final product.

- **Cost and Time**: Biologic manufacturing is expensive and time-consuming, requiring highly specialized facilities and skilled labor.

- **Scalability**: Producing biologics on a large scale while maintaining product consistency and quality is a significant challenge.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203



Figure.2 Regulation of Biologicals in different countries

3. Regulatory overview for Biologicals in USA

3.1 Regulatory Services for USA & Europe Regions

Regulatory gap analysis (review of product data), preparation of Regulatory mitigation plans and Regulatory strategies for 351(a) BLA submissions, 351 (k) BLA submissions and MAA submissions.

US Agent Services for Various Developmental Programs and Applications

- Biologics CMC writing in eCTD format for clinical trial applications (INDs/IMPDs) and MAAs/Biologics License Applications (BLAs)
- Regulatory publishing and submissions in eCTD/NeeS format
- Biologics CMC query responses/ information requests and end-to-end support for managing Complete Response Letters (CLRs)
- Product life cycle management and need-based Regulatory support (e.g., biological product deviation reports submission)
- Change controls management & CMC variations/supplements/amendments.
- Biological master file services for submission of information about the process, methods and other advanced technologies (e.g., gene sequencing techniques) that are proprietary in nature.

3.2. Regulatory Pathways for Biologics

Biologics are regulated under different legal frameworks depending on their specific nature. Two primary laws govern the approval and regulation of biologics in the U.S.:

a) Public Health Service Act (PHSA)

- **Biologics License Application (BLA)**: The **PHSA** provides the framework for the regulation of biologics in the U.S. under the Biologics Control Act of 1902**.** Under this law, biologic products must be approved through a Biologics License Application (BLA) submitted to the FDA.

- The PHSA requires that all biologics meet standards for purity, potency, and safety before they can be marketed.

- The FDA evaluates the clinical data and manufacturing processes involved in the production of biologics under the PHSA to ensure that they meet regulatory requirements.

b) Federal Food, Drug, and Cosmetic Act (FDCA)

- For certain types of biologics, such as biosimilar products, the FDA follows procedures under the FDCA**,** which regulates the approval of new drugs. The Biosimilars User Fee Act (BsUFA**)**, which amends the FDCA, provides the process for the approval of biosimilars (biologic products that are highly similar to an FDA-approved reference biologic).

3.3. Biologics License Application (BLA)

To market a new biologic in the U.S., manufacturers must submit a **Biologics License Application (BLA)** to the FDA. The BLA must include comprehensive data demonstrating the safety, efficacy, and quality of the product. The key components of a BLA submission are as follows:

- **Chemistry, Manufacturing, and Controls (CMC)**: Information about the product's composition, manufacturing process, quality controls, and stability. This includes detailed descriptions of the production process and evidence that the biologic meets quality and safety standards.

- **Preclinical Data**: Laboratory and animal studies that demonstrate the biological activity and safety profile of the product before clinical trials begin.

- **Clinical Data**: Results from human clinical trials (phases 1, 2, and 3) that assess the safety, efficacy, and immunogenicity of the biologic.

- **Labeling**: Proposed product labeling, including indications for use, dosage, administration instructions, and safety warnings.

- **Risk Management Plans**: Plans for post-marketing surveillance and risk mitigation, including monitoring for adverse effects after the product is on the market.

The FDA reviews the BLA, and once the application is approved, the biologic is granted a **Biologic License** and can be marketed and distributed in the U.S.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203



Figure.3 Marketing authorisation in US

3.4 Regulatory overview for Biologics in Canada

In Canada, biologics are regulated by **Health Canada** under the **Food and Drugs Act** and the **Biologics and Genetic Therapies Directorate (BGTD)**. Biologics in Canada, including vaccines, blood products, gene therapies, monoclonal antibodies, and biosimilars, are approved through the **New Drug Submission (NDS)** process for novel biologics, or the Supplementary New Drug Submission (SNDS) for changes to already approved biologics. The regulatory framework ensures that biologics meet stringent safety, efficacy, and quality standards. Health Canada evaluates preclinical and clinical data, manufacturing processes, and product labeling. Additionally, biologics may be eligible for expedited review through Priority Review **or** Notice of Compliance with conditions (NOC/c)**,** which allows for approval based on surrogate endpoints in cases of serious or life-threatening diseases. Biosimilars are regulated through a dedicated pathway, requiring evidence of similarity to the reference product in terms of quality, safety, and efficacy. Post-market surveillance is also a critical component of the regulatory process to ensure ongoing safety once the biologic is on the market.

3.5 Regulatory overview for Biologics in EUROPE

In Europe, biologics are regulated by the European Medicines Agency (EMA) under the EU Medicines Directive and Regulation (EC) No 726/2004**.** The approval process for biologics follows the centralized procedure, which allows for a single marketing authorization valid across all EU and EEA member states. The Committee for Medicinal Products for Human Use (CHMP) evaluates biologics, including vaccines, monoclonal antibodies, gene therapies, and biosimilars, based on clinical trial data, manufacturing quality, and safety. Biologics may be eligible for Conditional Marketing Authorization **or** Accelerated Assessment in cases of serious or life-threatening conditions, allowing for earlier access based on promising data. The Orphan Drug Designation is available for biologics aimed at treating rare diseases, offering incentives like market exclusivity and reduced fees. Biosimilars are approved through a streamlined pathway, requiring evidence of similarity to the reference product in terms of quality, safety, and efficacy. After approval, biologics are subject to ongoing post-market surveillance to monitor their long-term safety. The EMA's regulatory framework ensures that biologics meet high standards while facilitating timely access to innovative treatments across Europe.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203



Figure.4 Marketing authorisation in EU

Table 1 : Principal differences between US, Canada, Europe

PARAMETERS	US	CANADA	EUROPE
Regulatory authority	United State Food & Drug Administration (USFDA) (CBER	Health Canada	European Medicines Agency (EMA
Regulated under name	vaccines, Blood	Drugs and Health products (Biologics)	Human regulatory (Biosimilars)
Registration process	One registration process	One registration process	1.National Authorization Procedure 2. Decentralized Procedure 3.Mutual Recognition Procedure 4.Centralized Procedure
Dossier Format	ICH CTD	ICH CTD	ICH CTD

Table 2: Comparison of Stability Parameters

PARAMETERS	US	CANADA	EUROPE
Stability Zone	II	I	I
Stability Zone Name	Subtropical Zone	Temperate Zone	Temperate Zone
Long term stability	25°C±2°C& 60% RH ±5% RH	21°C ±2°C & 45%RH ±5% RH	21°C ±°C & 45% RH ±5% RH

4. Conclusions

A comparison of the marketing authorization requirements for regulated and emerging markets reveals that all countries generally adhere to **ICH (International Council for Harmonisation)** guidelines. The primary goal of the regulations governing medicinal products in regions such as the United States, Europe,and Canada is to safeguard public health. Government regulatory agencies are responsible for ensuring that pharmaceutical companies comply with these regulations. Laws are in place to guarantee that drugs are manufactured, tested, and distributed according to stringent guidelines, thereby ensuring their safety and protecting patient well-being.

REFERENCES:

1. Regulatory Affairs from Wikipedia, the free encyclopedia modified on 7th April available at http,//en.wikipedia.org/wiki/Regulatory_ Affairs.
2. International regulatory affair updates, 2005. available at http,//www.iraup.com/about.php
3. Douglas J Pisano and David S. Mantus. Text book of FDA Regulatory Affairs A Guide for Prescription Drugs, Medical Devices, and Biologics' Second Edition.
4. Regulatory Affairs brought by learning plus, inc. available at http,//www.cgmp.
5. Subash Philip, Ansa Philip, ―The Scope of Regulatory Affairs in the Pharmaceutical Industry‖, Hygeia.J.D.Med, 2010; 2(1): 1-6.
6. G. Sushma, Subal debnath, Santhosh Kumar C, Atul N Chandu, ―Quality and regulatory affairs of herbal drugs: A world-wide Review‖, Indo American Journal of Pharmaceutical Research, 2011; 1(5): 389-396.
7. D. Sreedhar, G.Subramanian, M. Sreenivasa Reddy and N.Udupa, ―need for the introduction of regulatory affairs in the pharmacy curriculum‖, Health Administrator vol. XIX Number 1: 51-52.
8. Naishi Kirtikumar, Dilip Maheshwari, ―Documentation Requirements for Generic Drug Application to be marketed in India- A Review‖, JPSBR., 2014; 4(4): 237-242.
9. 3. Kuhlmann J. Int. Journal of Clinical Pharmacology and Therapeutics. 1999; 37(12):575-83.
10. Bhatt A. Indian Journal of Pharmacology. 2004; 36(4):207-8.

How to cite this article:
Leelavathi A et al. Ijppr.Human, 2025; Vol. 31 (6): 472-480.

Conflict of Interest Statement: All authors have nothing else to disclose.